NCT06253117 (PirfenidoneRAP) is a Phase 2 clinical trial of Pirfenidone in Recurrent Acute Pancreatitis, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT06253117?

NCT06253117 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT06253117?

Interventions in NCT06253117: Pirfenidone, Placebo.

What condition does NCT06253117 study?

NCT06253117 studies Recurrent Acute Pancreatitis.

Is NCT06253117 still recruiting?

NCT06253117 is currently recruiting now. Last updated 14 October 2025.

Last reviewed 2025-10-14 · How we verify

NCT06253117: PirfenidoneRAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.

Recruiting now Phase 2 Last updated 14 October 2025

What this trial tests

Phase 2 trial testing Pirfenidone in Recurrent Acute Pancreatitis in 60 participants. Currently enrolling.

Timeline

27 June 2024

Primary endpoint
1 September 2028

1 September 2028

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	27 June 2024
Primary completion	1 September 2028
Estimated completion	1 September 2028
Sites	2 locations across United States

Drugs / interventions tested

Pirfenidone — full drug profile →
Placebo

Conditions studied

Recurrent Acute Pancreatitis — all drugs for Recurrent Acute Pancreatitis →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 to 85, any sex, with Recurrent Acute Pancreatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immune markers of severe acute pancreatitis.
Lee PJ, Papachristou GI, Speake C, Lacy-Hulbert A. · · 2024 · cited 16× · PMID 38967941 · DOI 10.1097/mog.0000000000001053

Verify or expand the search:

Other trials of Pirfenidone

Trials testing the same drug.

NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07082842 — Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF · Phase 3 · not yet recruiting
NCT07015398 — A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in · Phase 1 · completed
NCT06485635 — Real-life-persistence to Antifibrotic Treatments · completed
NCT06484153 — Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcin · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Recurrent Acute Pancreatitis

Currently open trials in the same condition.

NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
NCT06185621 — The Effect of Aspirin on Recurrent Acute Pancreatitis · NA · recruiting
NCT04647097 — Preventing the Recurrence of Acute Pancreatitis by Alcohol and Smoking Cessation · NA · recruiting
NCT06651580 — Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Stud · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06253117 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 14 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06253117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing